Endo International plc
ENDPDelisted Sep 14, 2022- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001593034
Endo International plc was delisted on Sep 14, 2022; its insiders filed their last Form 4 on Aug 17, 2022; 153 institutions reported holding it in 13F filings for Q2 2022, worth $65.0M in total; no superinvestor held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:38 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 6, 2024 | Mar 6, 2023 | Feb 28, 2022 | Feb 25, 2021 | Feb 26, 2020 |
| Revenue | $2.01B | $2.32B | $2.99B | $2.90B | $2.91B |
| Cost of revenue | $946.4M | $1.09B | $1.22B | $1.44B | $1.57B |
| Research and development | $115.5M | $128.0M | $148.6M | $158.9M | $130.7M |
| Selling, general and administrative | $567.7M | $777.2M | $861.8M | $698.5M | $632.4M |
| Interest expense | $0 | $349.8M | $562.4M | $532.9M | – |
| Income tax | $55.9M | $21.5M | $22.5M | -$274.0M | $15.7M |
| Net income | -$2.45B | -$2.92B | -$613.2M | $183.9M | -$422.6M |
| EPS, basic | $-10.42 | $-12.45 | $-2.63 | $0.80 | $-1.87 |
| EPS, diluted | $-10.42 | $-12.45 | $-2.63 | $0.79 | $-1.87 |
| Weighted shares, basic | 235.2M | 234.8M | 232.8M | 229.3M | 226.1M |
| Weighted shares, diluted | 235.2M | 234.8M | 232.8M | 233.7M | 226.1M |
| Margins and growth | |||||
| Net margin | -121.8% | -126.1% | -20.5% | 6.3% | -14.5% |
| Revenue growth, year over year | −13.3% | −22.5% | +3.1% | −0.4% | −1.1% |
| Net income growth, year over year | – | – | −433.4% | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 6, 2024 | Mar 6, 2023 | Feb 28, 2022 | Feb 25, 2021 | Feb 26, 2020 |
| Cash and equivalents | $777.9M | $1.02B | $1.51B | $1.21B | $1.45B |
| Accounts receivable | $386.9M | $494.0M | $592.0M | $511.3M | $468.0M |
| Inventory | $246.0M | $274.5M | $283.6M | $352.3M | $327.9M |
| Total current assets | $1.67B | $2.08B | $2.71B | $2.41B | $2.59B |
| Property, plant and equipment | – | – | – | – | $504.9M |
| Goodwill | $1.35B | $1.35B | $3.20B | $3.56B | $3.60B |
| Intangible assets | $1.48B | $1.73B | $2.36B | $2.74B | $2.57B |
| Total assets | $5.14B | $5.76B | $8.77B | $9.26B | $9.39B |
| Short-term debt | – | $0 | $200.3M | $34.1M | $34.1M |
| Total current liabilities | $538.8M | $689.6M | $1.63B | $1.25B | $1.46B |
| Long-term debt | $8.15B | $0 | $8.05B | $8.28B | $8.36B |
| Shareholders' equity | -$6.60B | -$4.16B | -$1.24B | -$647.9M | -$866.5M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 6, 2024 | Mar 6, 2023 | Feb 28, 2022 | Feb 25, 2021 | Feb 26, 2020 |
| Operating cash flow | $435.1M | $269.2M | $411.1M | $397.4M | $98.1M |
| Capital expenditures | $94.3M | $99.7M | $77.9M | $70.0M | $63.9M |
| Free cash flow | $340.8M | $169.5M | $333.1M | $327.4M | $34.2M |
| Depreciation and amortization | $306.4M | $391.6M | $457.1M | $518.8M | $69.0M |
| Stock-based compensation | $11.2M | $17.3M | $30.0M | $41.4M | $59.1M |
| Investing cash flow | -$49.8M | -$133.1M | -$59.5M | -$624.9M | -$60.2M |
| Financing cash flow | -$604.6M | -$513.9M | -$105.5M | -$108.6M | $204.6M |
| Net change in cash | -$218.6M | -$382.1M | $246.3M | -$335.4M | $243.6M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 0.6% | 0.7% | 1.0% | 1.4% | 2.0% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Feb 28, 2024 | 235.2M | 0.0% | SEC |
| Oct 30, 2023 | 235.2M | 0.0% | SEC |
| Aug 1, 2023 | 235.2M | 0.0% | SEC |
| May 1, 2023 | 235.2M | 0.0% | SEC |
| Feb 27, 2023 | 235.2M | +0.6% | SEC |
| Nov 1, 2022 | 235.2M | +0.7% | SEC |
| Aug 1, 2022 | 235.1M | +0.7% | SEC |
| Apr 28, 2022 | 235.1M | +0.8% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.